The follicular helper T cells (T FH ) seemed to be expressed in several subsets of T-cell lymphomas. However, their expression in cutaneous T-cell lymphomas (CTCLs) has been rarely described. We investigated the clinical features, histopathological morphology, and expression of T FH markers in CTCLs. Forty-nine patients (24 men and 25 women) diagnosed with CTCL were examined, 25 patients with mycosis fungoides (MF) and 24 with other CTCLs. Immunohistochemical staining for CD10, Bcl-6, inducible costimulator, CXCL13, and PD-1 were performed. Relation between PD-1 and clinical course in MF was evaluated. PD-1 was detected in 21 of 25 (84.0%) MF cases and in 11 of 24 (45.8%) other CTCL cases. Bcl-6, CXCL13, inducible costimulator, and CD10 were occasionally expressed in most T-cell lymphomas, including MF. The staining for PD-1 was negative in all the MF cases with large-cell transformation. No correlation was observed between disease course and PD-1 expression rate in the MF cases. In conclusion, among the T FH markers, PD-1 was most frequently expressed in CTCL. PD-1 was expressed in most MF. PD-1 expression rates were significantly higher in MF than in other CTCLs. FIGURE 1. Results of immunohistochemical staining for PD-1. The expression level was categorized as grade 0 to 3 (by percentage of positive tumor cells graded on a scale of 0-3; 0 = 0%-10%, 1 = 11%-40%, 2 = 41%-70%, 3 = 71%-100%). Most MF specimens showed high PD-1 expression, whereas some CTCLs showed low expression (original magnification ·200). ALCL, anaplastic large-cell lymphoma; SPTCL, subcutaneous panniculitis-like T-cell lymphoma.
INTRODUCTION
Follicular helper T cells (T FH ) are a specific subset of CD4 + helper T cells (T H ), which are normally found in the germinal centers of the B-cell follicles. The T FH cells help B cells to differentiate into long-lived antibody-secreting plasma cells or memory B cells. The T FH cells can be distinguished from subtypes T H 1 and T H 2 by using several criteria, which include the expression of chemokine CXCL13, the costimulatory molecules PD-1 and inducible costimulator (ICOS), and the transcription factor Bcl-6. 1, 2 Some T-cell lymphomas express T FH -cell markers. The gene expression profiling studies of angioimmunoblastic T-cell lymphoma (AITL) have demonstrated that the neoplastic T cells are derived from the T FH cells. 3 The neoplastic T cells in AITL indeed express CD10, Bcl-6, ICOS, CXCL13, and PD-1. 4, 5 Recently, follicular peripheral T-cell lymphoma (PTCL), a subset of nodal PTCL with a follicular growth pattern, has been identified. These lymphomas have been shown to express T FH markers, and may show overlapping features with AITL. 6 In primary cutaneous CD4 + small/medium-sized pleomorphic T-cell lymphoma, atypical large CD4 + cells were positive for T FH markers, 7 suggesting that they were derived from T FH cells.
However, in cutaneous T-cell lymphoma (CTCL), T FH -cell expressions have been rarely described. Recently, Battistella et al 8 reported an original series of 5 primary CTCLs showing expression of T FH markers, and proposed naming them as primary cutaneous T FH -cell lymphomas. More recently, several mycosis fungoides (MF) cases positive for the T FH markers were reported. Meyerson et al 9 identified 8 cases diagnosed with MF or Sézary syndrome. The results of immunohistochemical studies revealed that some cases of lymphoma cells expressed CD10, Bcl-6, PD-1, and occasionally, CXCL13. In addition, intertriginous MF 10 and CD4/CD8 double-negative MF with T FH markers expression cases 11 have been reported. However, identification of T FH cells in CTCLs is difficult because of the low number of cases.
In this study, the expression of T FH -cell markers in CTCL was investigated. We attempted to determine whether follicular T-cell antigens could be used to differentiate various forms of CTCL and determine their prognosis.
MATERIALS AND METHODS

Subjects
Forty-nine cases of primary CTCL (24 men and 25 women) diagnosed at the Department of Dermatology, Ajou University Hospital, Suwon, Korea, between January 2000 and December 2011 were examined. The diagnosis of CTCL was made on the basis of the clinical features and the results of histopathological analyses and immunohistochemical studies. Twenty-five patients with MF, 9 with lymphomatoid papulosis, 8 with anaplastic large-cell lymphoma, 4 with subcutaneous panniculitis-like T-cell lymphoma, 2 with PTCL, and 1 with NK/T-cell lymphoma were included in the study. The mean age of the patients was 44.8 years (range, 14-91 years). This study was approved by the institutional review board of the Ajou University Hospital (IRB number: AJIRB-MED-KSP-12-201).
Clinical Evaluation
The charts of 49 patients with clinicopathologically proven CTCL were reviewed. The clinical features were investigated with respect to age, sex, location of the skin lesions, duration of symptoms at presentation, cutaneous manifestations, treatment, and disease course.
Histopathological and Immunohistochemical Evaluation
Hematoxylin and eosin (H&E) staining was used to study the general histopathological changes in the skin lesions of the CTCL. Expression of T FH markers in reactive versus neoplastic cells is crucial. Because most of the infiltrated cells in MF were positive for CD4 in our cases, we regarded them as neoplastic cells. In other lymphomas, neoplastic cells were judged from the morphology of the cells.
Immunohistochemical staining was performed, using antibodies against PD-1 (1:100, mouse monoclonal antibody; Cell Marque), Bcl-6 (1:100, mouse monoclonal antibody; Cell Marque), CXCL13 (1:10, goat polyclonal antibody; R&D Systems), ICOS (1:100, rabbit polyclonal antibody; Spring Bioscience), and CD10 (1:100, mouse monoclonal antibody; Novocastra, United Kingdom). Expression of the T FH markers was graded on the basis of the extent of staining (by percentage of positive tumor cells graded on a scale of 0-3; 0 = 0%-10%, 1 = 11%-40%, 2 = 41%-70%, 3 = 71%-100%). Positive cases were defined if positive tumor cells were 11% or more.
Statistical Analysis
A x 2 test was performed using the SPSS Statistics Desktop 20.0.0 software (IBM, Armonk, NY) to evaluate sensitivities and specificities for MF and other CTCLs with respect to PD-1. A P value ,0.05 was considered statistically significant.
RESULTS
Clinical Findings
The skin sites of disease involvement in CTCL were diverse: multiple sites (trunk, extremities, and/or head and neck area; 21/49), extremities (17/49), trunk (7/49), and head and neck area (4/49). The patients with MF consisted of 14 men and 11 women, with an average age of 44.8 years, ranging from 16 to 83 years. The skin sites of disease involvement showed more involvement in multiple sites than in other CTCL: multiple sites (16/25), trunk (5/25), extremities (3/25), and the head and neck area (1/25). The average duration of the CTCL was 4.0 years. The erythematous patches or plaques typical for MF were seen in 23 of the 25 patients (patches, 18; plaques, 9). Papules were observed in 2 of the 25 patients, and tumors or nodules were seen in 3 of the 25 patients. Hypopigmented patches were observed in 2 of the 25 patients. Generalized erythema was not observed. Clinical follow-up dates of 19 patients with MF were reviewed as available. Mean follow-up period was 2.2 years with follow-up failure for 6 patients. Although the condition of 5 patients improved, 12 patients showed limited disease progression or recurrence at last follow-up. Two patients died of the disease, 2 and 2.3 years after diagnosis.
Results of Immunohistochemical Staining
Five T FH markers in 49 primary CTCL tissues were investigated ( Figs. 1 and 2 ). PD-1 was detected in 21 of 25 (84.0%) MF cases and in 11 of 24 (45.8%) other CTCL cases. However, Bcl-6, CXCL13, and ICOS were scantly expressed in most T-cell lymphomas, including MF (Fig. 3 ). CD10 expression was not detected in any of the cases. Three MF cases with large-cell transformation were enrolled in this study, and all were negative for PD-1 expression.
Statistical Analysis
The cases were assorted into 2 groups: MF and other CTCL. The PD-1 expression was more frequent in MFs than other CTCLs (P , 0.05, Fig. 3 ). Specificities for PD-1, Bcl-6, CXCL13, and ICOS were 76.5%, 51.4%, 46.9%, and 52.8%, respectively; and sensitivities for PD-1, Bcl-6, CXCL13, and ICOS were 65.6%, 57.1%, 47.1%, and 61.5%, respectively.
Relation Between PD-1 Expression and Clinical Course of MF
Excluding patients who were lost to follow-up, 2 of 4 PD-1-negative patients with MF (50%) and 6 of 15 PD-1positive patients with MF (40%) showed progressive course despite treatment or died of disease. No correlation was observed between disease course and PD-1 expression rate in MF cases.
DISCUSSION
The expression of T FH markers in primary CTCL was evaluated under the assumption that some tumor cells may be derived from CD4 + T cells and those T FH cells are a subset of CD4 + T H .
The T FH -cell functions are mediated through the production of cytokines and through the engagement of costimulatory molecules (such as ICOS, CD28, CD40L, and PD-1) and other receptors (SLAM-associated protein, CXCR5, etc) that favor strong interactions with B cells and consequently B-cell responses. Some of these cytokines, costimulatory molecules, and receptors can be used as markers to identify reactive or neoplastic T FH cells by using flow cytometry or by performing immunohistochemical analyses on routinely fixed tissue samples. For diagnostic purposes, CXCL13, PD-1, ICOS, and Bcl-6 may represent the most useful immunohistochemical T FH markers. 1 CXCL13 is a chemokine, which is critical for B-cell recruitment into the germinal centers and for B-cell activation. The transcription factor Bcl-6 drives T FH formation. 12 Bcl-6 expression in T FH cells upregulates the expression of CXCR5, ICOS, PD-1, IL-21R, and IL-6R. Furthermore, the ICOS molecule, a CD28 homolog implicated in T-cell activation and differentiation, interacts with counter receptors on B cells. 1 In this study, these markers were rarely expressed in most T-cell lymphomas, including MF. CD10 is a cell-surface glycoprotein with endopeptidase activity that is expressed on a variety of hematopoietic and epithelial cells. 13 CD10 is also expressed on a subset of CD4 + T cells referred to as T FH cells, which reside in the lymph node follicle germinal center. However, CD10 expression was not detected in all of the cases in this study. Moreover, identification of tumor cells in skin biopsies by using immunohistochemical analyses to detect CD10 expression on tumor cells is complicated because tumor-associated dermal fibroblasts have also been shown to express CD10. 14 As an alternative to immunohistochemical tests, CD10 on tumor cells can be detected by using flow cytometry. 15 PD-1 cell-surface protein, an inhibitory member of the CD28 costimulatory receptor family, is a negative regulator of T-cell activity that presumably regulates selection and survival of germinal center B cells. 16 In this study, PD-1 expression was observed in higher number of MF cases than in other CTCL cases. Moreover, PD-1 expression showed a significant correlation with MF. Previous studies have shown similar PD-1 expression rates in MF. 17, 18 Several cases of CTCL with T FH -cell phenotype have been reported. Battistella et al 8 reported 5 such cases and suggested that these CTCLs with the expression of T FH -cell markers comprised a new phenotype. They also proposed provisional criteria for these lymphomas, which include: clinical symptoms such as development of papules, plaques, and nodules (no patch stage); no B-cell lymphoma systemic signs; and histopathological features such as diffuse dermal infiltrate of pleomorphic medium to large CD4 + T cells, prominent B-cell component with some immunoblasts, T FH -cell phenotype of neoplastic cells (ie, $2 positive markers among CD10, Bcl6, PD-1, CXCL13, or ICOS). In this study, however, the majority of the T FH marker (+) MF cases showed patch stage, and a B-cell component was not histologically prominent. Thus, the study cases did not match the new phenotype defined by Battistella et al.
Most of the MF samples expressed T FH -cell markers, and PD-1 expression rates were significantly higher in the MF samples than in the other CTCL samples. These findings suggest that some MF tumor cells might consist of T FH cells. The recently reported MF cases that are positive for the T FH marker raise this possibility. [9] [10] [11] In addition, the result in this study suggests that PD-1 can be a MF-sensitive marker, and it might be useful in differentiating MF from other CTCLs.
A high PD-1 expression rate in MF might suggest that some MF tumor cells were derived from T FH cells. However, no single marker, including PD-1, Bcl-6, CXCL13, ICOS, and CD10, was found to be specific for the T FH -cell lineage.
To prove the derivation from follicular helper cell, a combination of various T FH -cell marker expressions is required. 19 As in other studies, PD-1 expression was much higher than that of other T FH markers. It seems that PD-1 is not really specific for T FH cells. In addition, the expression of T FH markers in several cases of subcutaneous panniculitis-like T-cell lymphomas, which are usually CD4 2 and CD8 + , could not be explained. Additional studies with a larger number of patients are needed to confirm this finding.
Large-cell transformation in MF is defined as the presence of large cells at a number that exceeds 25% of the cell population. 20 Large-cell transformation is most frequently diagnosed in patients with more advanced disease, and it is often associated with a poor response to treatment and poor prognosis. Studies have shown that MF and large-cell transformation have a common clonal origin; however, the morphologic, phenotypic, and molecular risk factors that result in the development of large-cell transformation are largely unknown. 21 The results of a previous study suggested that expression of CD25 (interleukin-2R) may identify a subset of patients at risk for large-cell transformation. 22 In addition, some researchers have demonstrated correlation between large-cell transformation and an increase or decrease of regulatory T cells, 23,24 chromosomal tetraploidy, 25 or aneuploidy. 26 Recently, Kantekure et al 27 presented results of the immunohistochemical staining of the PD-1 expression in MF, which were based on the clinical and histological stages. PD-1 was expressed frequently in the early patch and plaques stages of MF, and it was expressed less frequently in the tumor stage of the lymphomas. Additionally, PD-1 expression was rarely detected in the large transformed lymphocytes. In this study, all the MF cases with large-cell transformation were negative for PD-1 expression, which is consistent with the results of a previous study. 27 Skin specimens had been obtained before the large-cell transformation for 2 of the 3 large-cell transformation cases. Additional PD-1 immunostaining was performed in those 2 specimens, and both were positive for PD-1. The loss of PD-1 expression in large-cell transformed cases is intriguing because it raises the possibility that PD-1 downregulation may be related to the biological process that ultimately results in large-cell transformation. Although additional studies with larger number of patients are needed to confirm this observation, our findings suggest that loss of PD-1 expression in MF may be a possible marker to predict large-cell transformation, with potential impact on treatment modalities and patient survival.
In conclusion, most MF samples expressed PD-1. PD-1 expression rates were significantly higher in MF than in other CTCLs. This implies that PD-1 might become a marker for MF if it will be confirmed in larger studies also from other centers. Interestingly, loss of PD-1 expression in large-cell transformation was identified. This finding suggests that PD-1 downregulation may be related the biological process that ultimately results in large-cell transformation.
